John B. Watkins, PharmD, MPH, BCPS

Articles by John B. Watkins, PharmD, MPH, BCPS

Impact of a Value-Based Formulary in Three Chronic Disease Cohorts

ByKai Yeung, PharmD, PhD,Anirban Basu, PhD,Zachary A. Marcum, PharmD, PhD,John B. Watkins, PharmD, MPH, BCPS,Sean D. Sullivan, PhD

March 27th 2017

A value-based formulary was implemented that used cost-effectiveness analysis to inform medication co-payments. Diabetes cohort expenditures decreased by $9 per member per month.

Latest Updated Articles

Impact of a Value-Based Formulary in Three Chronic Disease Cohorts
March 27th 2017

John B. Watkins, PharmD, MPH, BCPS

Articles by John B. Watkins, PharmD, MPH, BCPS

Impact of a Value-Based Formulary in Three Chronic Disease Cohorts

Latest Updated Articles

Trending on AJMC

FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes

Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD

Across the US, Obesity Care Still Lacks an Owner

GLP-1 Receptor Agonists Cut Ascites, Mortality in MASH

Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations